JNJ-79883960

JNJ-79883960 : Inhibitor of NLRP3

Structure

SERP Rating

In Cells

(2 ratings)

In Model Organisms

(2 ratings)

note: The Chemical Probes Portal only endorses compounds as chemical probes for use as specific and selective modulators of the proposed target if they receive three or more (3-4) stars.

Probe JNJ-79883960 is in the process of SERP review.

Please continue to check back for new reviews and commentary.

Information

NLRP3

Inhibitor

up to 10 µM

Additional Data

SGC image SGC Chemical Probe Collection

In Vitro Validations

No in Vitro Validations

In Cell Validations

In Vivo Data

Off-Target Selectivity Assesments

Probe Selectivity in Vitro:

Tested some of the other 11 human inflammasomes: A panel of inflammasome triggers was used to look at inhibition (with 10 µM of JNJ-79883960) of the NLRP3, NLRC4, Pyrin, AIM2 and NLRP1b inflammasome. Highly selective for the NLRP3 inflammasome.

Probe Selectivity in Vitro:

All analogs were clean in CEREP and DiscoverX kinase panel

I have extra information to add

SERP ratings and comments

SERP Ratings

In Cell Rating

In Model Organisms

SERP Comments:

JNJ-79883960 is a potent and selective inhibitor of the NLRP3 inflammasome. It is active in cells, thus suitable as in vitro chemical probe. Target engagement has been shown for the series, e.g. by cryo-EM structures. The probe is also suitable for in vivo work in mice, allowing subchronic dosing regimen. The compound is most likely peripherally restricted. To study in vivo effects in the brain, the probe NP3-253 is recommended (doi: 10.1021/acs.jmedchem.4c02350).

(last updated: 7 Dec 2025 )

SERP Ratings

In Cell Rating

In Model Organisms

SERP Comments:

The primary paper of JNJ-79883960 reports the biophysical characterisation of members of the same chemical series by nano-DSF, biochemical assay (ATP hydrolysis inhibition), HDX and a cryo-EM structure. There is therefore high confidence that JNJ-79883960 works by on-target binding of NLRP3. JNJ-79883960 is well tolerated in vivo. A dose up to 100 mg/kg in a preclinical rodent 14-day mini-tox experiment showed no adverse events, pathology or histopathological findings.

(last updated: 16 Dec 2025 )